A potential new antidepressant and antianxiety treatment with a unique mechanism of action has been developed by scientists at the University of Bath.
The compound has shown significant potential after studies in mice. The research is published in the British Journal of Pharmacology.
Around one in six adults will experience depression in their lifetimes. New drugs to treat depression in particular are needed because many existing antidepressants don’t work in up to 50% of patients. This new University of Bath compound, known as BU10119, works in a different way to the most common antidepressant drugs; selective serotonin reuptake inhibitors (SSRIs), and may therefore offer a new potential treatment for those in whom SSRIs don’t work.
Unlike SSRIs which target the serotonin system in the brain, BU10119 works by blocking receptors called kappa opioid receptors. Blocking these receptors has been shown to have anti-depressant like effects in mice.
In a series of laboratory trials, mice given BU10119 demonstrated behaviours consistent with providing antidepressant–like effects.
Dr Sarah Bailey, Senior Lecturer in the Department of Pharmacy & Pharmacology at the University of Bath, said: “I’m really quite excited by the potential of this compound. Developing new medicines is why I got into pharmacology and, in 20 years of research, this is the closest I have come to a new compound that might translate towards the clinic. It’s promising, but that said, we are still at an early stage, these experiments are in mice and further research is still required for example to establish safety.
“SSRIs can work very well for some patients, but we know they don’t work for everyone which is one reason why developing new antidepressant and antianxiety drugs could be really beneficial.”
The researchers were inspired to develop the compound after previous University of Bath research showed that a combination of two existing drugs, buprenorphine and naltrexone, had potential as an antidepressant. BU10119 combines the effects of this combination in one drug.
Professor Stephen Husbands, Head of Medicinal Chemistry at the University of Bath added: “This research builds on our previous work which showed that combining buprenorphine and naltrexone can give antidepressant effects in mice. By combining the effects of both drugs in one molecule we hope that a safe and effective drug will eventually be the outcome. BU10119 is part of a series of compounds now licensed to, and under development with, Orexigen Therapeutics.”
The study was funded a by a National Institute on Drug Abuse grant and a PhD scholarship from the Government of Saudi Arabia.
The University of Bath has signed the Concordat on Openness on Animal Research. The University is committed to enhancing our communications with the media and public about our research using animals. Find out more: http://www.bath.ac.uk/collections/animal-research/
Learn more: New drug shows potential as a different kind of antidepressant in mouse trials
The Latest on: Depression and anxiety
[google_news title=”” keyword=”depression and anxiety” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Pressure to be perfect raising burnout in parents, anxiety in childrenon May 9, 2024 at 12:36 am
Societal pressure to be perfect is increasing parental burnout and raising the risk of children suffering from stress, anxiety, and depression, a study revealed on Wednesday ...
- Psychedelic Toad Venom Shows Promise for New Depression Treatmenton May 8, 2024 at 12:00 pm
Scientists have mapped the structure of a psychedelic drug derived from the Colorado River toad, which seems to have antidepressant effects.
- Psychedelic Toad Venom Could Be Used To Treat Depression Based On New Evidenceon May 8, 2024 at 9:36 am
Modern science has dreamed up a wide variety of treatments for depression, anxiety, and other mental issues, and researchers may have stumbled across a ...
- Psychedelic toxins from toads could treat depression and anxietyon May 8, 2024 at 8:00 am
By Corryn WetzelA psychedelic compound secreted by a poisonous toad could help treat depression and anxiety, according to a study in mice.When frightened, Colorado river toads (Incilius alvarius) ...
- New guidelines for depression care emphasize patient-centred approachon May 7, 2024 at 5:00 pm
Psychiatrists and mental health professionals have a new standard for managing major depression, thanks to refreshed clinical guidelines published today by the Canadian Network for Mood and Anxiety ...
- Using AI and social media to track depression in communities could offer more reliable assessments than surveyson May 7, 2024 at 10:12 am
A study that used artificial intelligence (AI) and social media posts to assess the rates of depression and anxiety in nearly half of American counties found that the AI-generated measurements ...
- Thrive Postpartum introduces innovative platform and podcast to support mothers with postpartum depression and anxietyon May 7, 2024 at 5:35 am
Listen to this article Thrive Postpartum™ proudly announces the launch of its online platform and the premiere of its new podcast, “Let’s Thrive Postpartum,” designed specifically to support mothers ...
- There’s hope in the darkness of depression and anxietyon May 7, 2024 at 3:48 am
For many Christians, the pressure to always appear joyful and steadfast in their faith can exacerbate feelings of anxiety and depression. The expectation of being strong in their beliefs while ...
- Depression Newson May 6, 2024 at 4:59 pm
Brain Stimulation Treatment May Improve Depression, Anxiety in Older Adults Apr. 10, 2024 — A noninvasive brain stimulation treatment improved depression and anxiety symptoms among older adults ...
- Virtual reality could revolutionize mental-health treatments, including ketamine therapy, for conditions like depression and anxietyon May 2, 2024 at 7:25 am
Here's how virtual reality is transforming mental-health treatments such as ketamine therapy for conditions like depression, PTSD, and body dysmorphia.
via Google News and Bing News